Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cocrystal Pharma, Inc. (formerly known as BioZone Pharmaceuticals, Inc.) (NASDAQ: COCP) filed a class action complaint against the company’s officers and directors for alleged violations of the Securities Act of 1934 between September 23, 2013 and September 7, 2018. Cocrystal is a clinical stage biotechnology company that develops novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
View this information on the law firm’s Shareholder Rights Blog: https://www.robbinsarroyo.com/cocrystal-pharma/
Cocrytsal Pharma charged by the Securities and Exchange Commission (SEC) in fraudulent stock scheme
According to the complaint, BioZone was created in June 2011 through a reverse merger by a group of investors whose fraudulent stock manipulation scheme ultimately caused significant harm to unsuspecting investors. The controlling shareholders of BioZone engaged a stock promoter to tout Opko Health’s CEO Phillip Frost’s involvement in BioZone in exchange for below-market price BioZone shares.
Then, on January 3, 2014, BioZone announced it had finalized its merger with Cocrystal Discovery Inc., forming Cocrystal Pharma on April 15, 2014. Thereafter, Cocrystal Pharma repeatedly assured investors regarding the accuracy of its financial reporting, the disclosure of any material changes to the company’s internal control over financial reporting and the disclosure of all fraud. It therefore came as a surprise, when, on September 7, 2018, the SEC charged 10 individuals, including Cocrystal Pharma Director Phillip Frost and the controlling shareholders of BioZone, for participating in long-running fraudulent schemes that generated over $27 million from unlawful stock sales and caused significant harm to retail investors. On this news, shares of Cocrystal fell more than 15% over two days to close at $3.16 on September 11, 2018, and now trades at around $2.40.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Cocrystal Pharma Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm’s website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.